In addition, ATR inhibitor AZD6738 (ATRi) combines with radiation to generate CD8+ T cell-dependent responses in immunoproficient mouse models of cancer (Dillon et al., 2019; Sheng et al., 2020; Vendetti et al., 2018). Here, CD8A is linked to cancer.